Ratio Therapeutics Appoints Global Medical Leader Colin Hayward as Chief Medical Officer

Hayward brings over 26 years of experience in oncology, hematology, and rare diseases to lead Ratio's radiopharmaceutical pipeline

Mar. 12, 2026 at 5:00pm

Got story updates? Submit your updates here. ›

Ratio Therapeutics, a pharmaceutical company developing radiopharmaceuticals for cancer treatment and monitoring, has appointed Colin Hayward, MBBS, FFPM, as its new Chief Medical Officer. Dr. Hayward has over 26 years of global experience in the healthcare industry, with a focus on oncology, hematology, and rare diseases, including the last six years in radiopharmaceuticals and translational medicine.

Why it matters

Ratio Therapeutics is advancing its radiopharmaceutical pipeline, including the ATLAS trial, a Phase 1/2 study of [Ac-225]-RTX-2358 in patients with relapsed or refractory soft tissue sarcomas. Dr. Hayward's extensive experience in clinical development and medical affairs will be crucial in guiding the trial's design, execution, and oversight, ensuring robust data generation while maintaining high standards of patient care.

The details

Prior to joining Ratio, Dr. Hayward served as Chief Medical Officer at Telix Pharmaceuticals, where he led the Medical Affairs and Clinical Development teams, overseeing oncology, hematology, and rare disease programs, including first-in-human studies and regulatory interactions. Previously, he held leadership roles at Premier Research, Myriad Genetics, and Roche, managing international medical affairs, clinical development, and strategic drug development initiatives across multiple therapeutic areas.

  • Ratio Therapeutics announced the appointment of Dr. Colin Hayward as Chief Medical Officer on March 12, 2026.

The players

Ratio Therapeutics Inc.

A clinical-stage pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms.

Colin Hayward, MBBS, FFPM

The new Chief Medical Officer of Ratio Therapeutics, with over 26 years of global experience in the healthcare industry, including leadership in oncology, hematology, and rare diseases, with a focus on radiopharmaceuticals and translational medicine.

Dr. Jack Hoppin

The Chairman and Chief Executive Officer of Ratio Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“Colin joins Ratio at an important time as we advance our radiopharmaceutical pipeline and further progress the ATLAS trial, a Phase 1/2 study of [Ac-225]-RTX-2358 in patients with relapsed or refractory soft tissue sarcomas. His extensive experience in clinical development and medical affairs will be invaluable in guiding the trial's design, execution, and oversight, ensuring we generate robust data while maintaining the highest standards of patient care.”

— Dr. Jack Hoppin, Chairman and Chief Executive Officer of Ratio Therapeutics (PR Newswire)

“I am honored to join Ratio during such a dynamic period for the radiopharmaceutical industry. I look forward to working with the talented team to advance the ATLAS trial and our broader clinical programs. Ratio has the technology to make a meaningful impact for patients, and I am excited to help translate our targeted radiopharmaceuticals into effective therapies for those who need them most.”

— Dr. Colin Hayward, Chief Medical Officer of Ratio Therapeutics (PR Newswire)

The takeaway

Ratio Therapeutics has brought on a highly experienced global medical leader in Dr. Colin Hayward to guide the company's radiopharmaceutical pipeline, including the critical ATLAS trial, as it seeks to develop innovative cancer therapies that can make a meaningful impact for patients.